Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter
Zydus Is Nurturing New Molecules For The Future Even As Generics Pay Off For Now • Source: Shutterstock
The US Food and Drug Administration (FDA)’s negative review for Intercept Pharmaceuticals, Inc.’s obeticholic acid (OCA) has set off questions about the fate of other non-alcoholic steatohepatitis (NASH) drug hopefuls.
Among them is Zydus Lifesciences Limited, the sole Indian company evaluating a New Chemical Entity (NCE) saroglitazar magnesium against...
